THREAD
← Back

THREAD Launches No-Code, Fully Configurable Single Sign-On For Clinical Research Platform

Provides Research Sites and Study Teams with Enhanced, Unified Log-in Experience

CARY, N.C., MAY 14, 2024 – Thread, a leading decentralized research, eCOA and consulting services provider, today announced the launch of a fully configurable, no-code single sign-on (SSO) for the company’s clinical research platform. The new feature enhances and unifies the experience of researchers, study teams and participants utilizing Thread’s platform to collect, share and analyze clinical data.

Thread’s new solution removes the barriers of current industry SSO options, which typically require code libraries, application programming interfaces, custom development work and multiple validations. In addition to providing research stakeholders with a seamless login experience across multiple applications, Thread’s new feature:

  • Alleviates burden – all research sites use a single login from their own identity provider, eliminating the need for new credentials
  • Enhances flexibility – integrates and offers multiple identity providers to organizations’ needs
  • Improves efficiency - easily manages SSO access for study and sponsor users
  • Simplifies registration - no longer requires a separate password, streamlining the login and onboarding process
  • Streamlines password management – centralizes passwords using each organizations’ already selected SSO provider(s)
  • Enhances security – provides a comprehensive user access and audit log

“In listening to and working with our customers, we developed a modern SSO solution that enables research sites, study teams and platform users to enjoy a faster, easier and more unified experience,” said John Reites, co-founder and CEO, Thread. “We transformed what used to be a technology barrier that can take months with limited ability to scale into a no-code configurable solution that solves this challenge in a few clicks using your already selected identity provider.”

Leveraging many of the top Security Assertion Markup Language (SAML 2.0) identity provider applications, Thread’s SSO feature allows platform and study administrators to select, enable/disable, and add/remove identity providers or groups from their instance of Thread’s platform. Sponsors considering a decentralized trial approach, looking for a more modern eCOA solution, or wanting to learn more about this new SSO feature can contact THREAD or click here: www.threadresearch.com/sso.

##

About Thread

Thread’s® purpose is to leverage its decentralized research platform to enable studies for everyone, everywhere. The company’s uniquely combined clinical research technology and consulting services help life science organizations to design, operate, and scale next-generation research studies and electronic clinical outcome assessments (eCOA) programs for participants, sites and study teams. Through its comprehensive platform and scientific expertise, Thread empowers studies to be accessible, efficient and centered on the patient. Backed by health care investors Water Street Healthcare Partners and JLL Partners, Thread is recognized as a leader by Everest Group’s Decentralized Clinical Trial Product PEAK Matrix® Assessment 2021/2022 and positioned in the Leader's Category of the 2022 IDC MarketScape for R&D Decentralized Clinical Trial Technology Solutions Vendor Assessment 2022. Visit Threadresearch.com to learn more.

Media Contact:

Les Yates
Thread
Media@Threadresearch.com